MRL Ventures Fund
Investing in the Future

The MRL Ventures Fund (MRLV) team invests globally in early-stage, preclinical therapeutics companies to transform patient care.

Explore how the MRLV team of experienced life-sciences venture capital professionals are committed to supporting great entrepreneurs in their quest to create value through building companies that have a meaningful impact on health and disease.

About Us

The MRL Ventures Fund (MRLV) is the corporate venture arm of Merck & Co, Kenilworth, NJ and located in Cambridge, MA

The MRLV team is:

Looking for the highest quality, differentiated science that will redefine patient care

Committed to backing imaginative scientists and proven entrepreneurs

Agnostic to therapeutic area or modality

The MRLV investors do not ask for any product or technology rights as a condition of investment. We do not invest in medical devices, diagnostic platforms or digital health. For digital health opportunities, please visit Global Health Innovation Fund (GHI).


>$500 million of committed capital

Total Capital Raised for Portfolio

Delivering More than Capital


Seed and early-stage company investments

Therapeutics companies—from concept to IND. Investing $15-20 million per company, providing long-term, and committed capital

Lead or join a syndicate of investors and play an active role on company boards

Transparent and streamlined investment process

Company Involvement

Over the life of the company, the MRLV team will continue to provide capital and expertise. We protect the confidentiality of our current and future portfolio companies by providing a robust firewall from the rest of the corporation.

At a portfolio company’s choosing, MRLV investors can act as a conduit to the larger corporate organization to solicit advice / expertise.

Our Portfolio Companies


Acquired & IPOs

Our Team

The MRLV team of investors has years of accumulated experience as scientists, investors, entrepreneurs, and business development & licensing leaders in both biotechnology and pharmaceutical companies. This broad experience enables MRLV investors a rich engagement with portfolio companies and co-investors.

Peter Dudek, Ph.D.
President, MRLV

Christine Brennan, Ph.D.
Partner, MRLV

Diana Bernstein, Ph.D.
Senior Associate, MRLV

Olga Danilchanka, Ph.D.
Senior Associate, MRLV

Contact MRL Ventures Fund

MRL Ventures Fund is actively developing a portfolio of early-stage therapeutic companies, which are focused on delivering innovative therapies to improve patient care.

MRL Ventures Fund
320 Bent Street
4th Floor
Cambridge, MA 02141